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Abstract   
Studying gene-environment interactions requires that the amount and quality of the lifestyle data is 
comparable to what is available for the corresponding genomic data. Sweden has several crucial 
prerequisites for comprehensive longitudinal biomedical research, such as the personal identity 
number, the universally available national health care system, continuously updated population and 
health registries and a scientifically motivated population. LifeGene builds on these strengths to 
bridge the gap between basic research and clinical applications with particular attention to 
populations, through a unique design in a research-friendly setting.   
LifeGene is designed both as a prospective cohort study and an infrastructure with repeated contacts 
of study participants approximately every five years. Index persons aged 18-45 years old will be 
recruited and invited to include their household members (partner and any children). A 
comprehensive questionnaire addressing cutting-edge research questions will be administered 
through the web with short follow-ups annually. Biosamples and physical measurements will also be 
collected at baseline, and re-administered every five years thereafter. Event-based sampling will be a 
key feature of LifeGene. The household-based design will give the opportunity to involve young 
couples prior to and during pregnancy, allowing for the first study of children born into cohort with 
complete pre-and perinatal data from both the mother and father. Questions and sampling schemes 
will be tailored to the participants’ age and life events. The target of LifeGene is to enrol 500,000 
Swedes and follow them longitudinally for at least 20 years.  
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Introduction  
Background  
In only a few years the methods used to study genetics of complex traits have evolved almost beyond 
recognition. The result has been unprecedented advances in our understanding of the genetic 
architecture of almost all common complex diseases. The main driving force behind these discoveries 
has been the rapid development and application of genome-wide association studies (GWAS). 
Although there has been remarkable recent progress in defining the genetic basis of common 
complex diseases, a new generation of epidemiological studies that undertake standardised, fine-
scale phenotyping and exposure assessments of many thousands of individuals measured repeatedly 
during many years of follow-up will be required to maintain this trajectory. New approaches for 
storing, processing, and charactering the tissue samples collected in these individuals will be 
necessary, as will the application of novel, comprehensive, and multi-factorial statistical methods to 
analyse data harvested from these biosamples. 
Worldwide, there are several large-scale genetic epidemiological studies such as the UK Biobank (1), 
deCODE in Iceland (2), Millennium in Japan (3), the Kadoorie study of Chronic Diseases in China (4) 
and CONOR/HUNT in Norway (5). These studies focus on chronic diseases diagnosed later in life, and 
some also collect detailed data on lifestyle factors. There are, however, very few large prospective 
studies focusing on disorders that emerge early in life, in some instances during infancy or early 
adolescence. LifeLines in Holland (6), a three-generation population-based study with a household 
recruitment approach differs from most other ongoing cohorts because data on diseases with onset 
early in life is collected. The Norwegian Mother and Child Cohort study (MoBa) (7), ALSPAC (the Avon 
Longitudinal Study of Parents and Children) (8) and the US National Child Study (9) have followed 
pregnant mothers from early pregnancy and their offspring throughout childhood, whilst other 
prospective birth cohort studies were brought together under the Global Asthma and Allergen 
European Network (Ga2len) (10). The Southampton Women's Survey (11) is of particular interest 
because it collected parental exposure data before the pregnancy and thus could assess associations 
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to perinatal and infant outcomes. Pre-pregnancy exposure data are also likely to be valuable in long-
term studies of chronic disease later in life, although to date no such studies have been undertaken. 
Sweden and other Nordic countries have several crucial prerequisites for comprehensive longitudinal 
biomedical research, due to the personal identity number, the universally available national health 
care system, continuously updated population and health registries and a scientifically motivated 
population. As a complement to the register-based epidemiologic tradition, Sweden is also at the 
forefront of developing and implementing information technology, cutting edge biotechnology and 
biobanking. In order to adequately address gene-environment interactions, acquisition of phenotype 
and exposure information repeatedly, biosamples and physiological assessment are important. A 
prospective study combining information on exposures as early as pre-conception and in early life 
throughout young and mid-adulthood, with the possibility to study a variety of diseases with onset 
relatively early in life and co-morbidities later in life will open up new research opportunities.  
 
LifeGene is designed as a prospective cohort study with an infrastructure that allows repeated 
contacts of study participants approximately every five years, and short follow-ups annually. 
Recruitment of index people aged 18-45 years old who are invited to include their household 
members (other adults and any children) increases the opportunity to involve young couples prior to 
and during pregnancy, allowing for the first study of children born into cohort with complete pre- 
and perinatal data from both the mother and father. Other types of event-based sampling, i.e. data 
collection initiated as a result of a relevant event, such as an accident or influenza, is a key feature of 
LifeGene. A comprehensive web-based questionnaire comprised of multifaceted questions 
concerning phenotypes and exposures is administered at baseline, briefly followed-up annually, and 
re-administered every five years thereafter. Biosamples are collected and stored in a manner that 
facilitates the full range of ‘omics´, and physical measurements are also sampled repeatedly at five 
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year intervals. Questions and sampling schemes will be tailored to the participants’ age and life 
events. The target of LifeGene is to enrol 500,000 Swedes and follow them for at least 20 years.  
Methods and planning process  
In the early phases of planning Life Gene, multiple workshops and plenary sessions with invited 
international and national experts in a variety of diseases, genetic epidemiology, environmental 
epidemiology, and molecular genetics were organised during which the optimal LifeGene sample 
design, research questions that could be addressed with a prospective cohort, biological measures 
and phenotype and exposures were discussed.  
Separate working groups focusing on six broad phenotypic domains: infections, inflammation and 
allergy, malignant diseases, metabolic and cardiovascular disorders, musculoskeletal disorders and 
neuro-psychiatric disorders were established. In addition, a working group was established to discuss 
lifestyle factors such as physical activity and diet. Each working group was invited to present their 
area of research and the rationale for participation in LifeGene, along with preferred study design 
and optimal measures to include in questionnaires, biosamples and physical assessments. Three 
working groups focusing on infrastructure issues were also created: Biostatistics, biosampling and 
biobanking, and IT-infrastructure. Based on the combined recommendations of all groups, study 
design, recruitment and assessment schemes and protocols were established.  
Infectious diseases 
Outcomes of exposures to infectious agents are shaped by genetic background, exposure history to 
pathogens (or antigens in general, including vaccines), along with innate and adaptive immune 
response. Exposure to infectious agents has a broader impact on health and disease as compared to 
infections strictu sensu. Chronic inflammation, in part induced by infection, may impact on a number 
of diseases; prime examples of infections associated with malignant transformation are infections 
with Helicobacter pylori or human papilloma virus type 16. Perhaps the most recent report which 
links a retroviral infection with chronic fatigue syndrome shows that gauging infections entails far 
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more than just the examination of acute clinical infections. It also showed that retrospective analysis 
of old diseases may lead to the identification of novel pathogens (12). Novel and more sensitive 
methods to detect infectious pathogens as well as gauging relevant immune responses will help 
elucidate associations between infections and clinical syndromes. 
Pathogenicity of infectious agents is in part determined by the intricate host-pathogen relationship, 
which can be captured in a LifeGene grid of household interviews and biological sampling. An event-
based sampling study design allows linkage of clinically and biologically relevant events with the 
detection of infectious agents. An exercise in this context was proposed for the LifeGene pilot, which 
addressed Influenza-like-illnesses (ILI), described further on page 24.  
Other information relevant to infectious and viral diseases, such as travel, sexual behaviour, and 
vaccination will also be collected.  
Inflammation and allergy  
Inflammation is a key factor in allergy and asthma as well as in rheumatic diseases, multiple sclerosis 
and other autoimmune diseases. It also plays an important role in cardiovascular, musculoskeletal 
and periodontal diseases. Important research questions include the role of factors pre-conception for 
disease development in the offspring, which may be mediated by epigenetic mechanisms. A LifeGene 
birth cohort design would also be uniquely suited for addressing questions related to fetal growth. 
Furthermore, research questions on gene-environment interactions are paramount and a wide 
variety of early life exposure and conditions are of interest, such as nutrition, infections, maternal 
stress, smoking and obesity, as well as exposure to allergens and ambient air pollution.  
Special focus for protocol development was given to recruitment of pregnant mothers and their 
partners, including questionnaires and biosamples before and during pregnancy, as well as on 
extensive long-term follow-up of children born into the cohort. This group is of prime interest also for 
many other research questions, such as testing and providing mechanistic explanations for the 
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Barker hypothesis (13). Women in the LifeGene cohort who become pregnant were proposed to 
answer extensive questionnaires at gestational week 10-12 and at week 26-28, and biological 
samples to be taken using the same methodology as for the full cohort. Cord blood and maternal 
blood at delivery were also proposed and the child to be followed up with questionnaires at 4 
months and then at 1 year of age, followed by yearly questionnaires. In subgroups additional 
biosamples may be obtained on several occasions during the first two years of life.  
Malignant diseases 
Progress in cancer epidemiology has been remarkable during the last decades. Several malignancies 
– including those predominantly caused by tobacco, alcohol and certain oncogenic infections (e.g. 
hepatitis virus B and C, human papilloma virus and helicobacter pylori) – are now largely preventable. 
At the same time, progress has been limited or non-existent in other areas. Indeed, the causes of 
major cancer sites and types remain enigmatic. Prostate cancer, lymphomas, leukaemia and 
testicular cancer are salient examples.  
The cancer working group agreed that LifeGene would provide unparallel novel opportunities to 
reveal genetic and environmental causes of cancer. No other existing study combines the size of 
LifeGene with opportunities for repeated exposure measurement starting early in life, an extensive 
biobank allowing studies of biomarkers and genes with the convenience in Sweden of retrieving 
tumor tissue from pathology departments. As a corollary, LifeGene provides the opportunities to 
take a life course approach to cancer etiology; to accommodate emerging hypotheses through 
repeated exposure assessment by creative application of e-epidemiology; and to apply novel 
molecular techniques for refined – and perhaps etiologically more relevant – phenotypic subgrouping 
of cancer sites and types. The intense methodologic development in studies of gene-environment 
interactions will only make LifeGene more informative over time. 
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Metabolic and cardiovascular disorders 
The current global increase of obesity and type 2 diabetes incidence has taken epidemic proportions, 
and even if this is almost certainly due to a global shift towards more obesogenic behaviours, such as 
physical inactivity and caloric dense diet, susceptibility to these conditions varies greatly from one 
person to the next and tends to segregate within families, irrespective of lifestyle. Furthermore, the 
response to lifestyle interventions differs markedly from one person to the next, which also 
reinforces the hypothesis that metabolic and cardiovascular disorders emerge through a complex 
interaction of genetic and environmental factors. LifeGene provides a unique opportunity to study 
such interactions in detail with the possibility to address primordial, early-life factors and the role of 
longitudinal changes for the development of these diseases. 
The collection and storage of DNA, serum, plasma and urine allows for a core set of selected 
biomarkers, of which most are highly relevant for metabolic and cardiovascular disorders, to be 
analysed in front-end chemistry, and for subsequent analyses of genetic markers, proteins and 
metabolites in frozen specimens. As HbA1c is introduced for diagnosis of diabetes in many countries, 
measurement of HbA1c could provide a valuable estimate of the proportion of people with clearly 
abnormal glucose tolerance in the age group.   
Musculoskeletal disorders  
Musculoskeletal problems are commonly related to injuries, degenerative changes or from still 
unknown causes. With impaired functioning and pain as the dominant consequences for the 
individual, they bring high costs for the society (14).  
The high incidence of osteoporotic fractures in Sweden, and other Scandinavian countries, is an 
observation that cannot readily be explained by known lifestyle or genetic determinants, climate or 
longevity. Osteoarthritis, back and shoulder pain are common reasons for disabling pain and sick 
leave. There is also emerging evidence for an interaction between bone and the endocrine system. 
LifeGene will provide opportunities to combine metabolic information with information on bone 
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density and fracture risk. LifeGene will examine changes in bone mineral density, bone structure and 
body composition in a subgroup of individuals. The diagnoses of clinically manifest arthritis can be 
obtained from Swedish registries, but LifeGene will provide an opportunity to detect pre-clinical 
biomarkers for the diseases, and to furthermore evaluate the relative importance of genetic 
susceptibility of arthritis compared to life-style behaviours.  
Worldwide, injuries are one of the major causes of death, disability and health care consumption at 
all ages below 60. Sports, play, traffic accidents and intentional injuries (violence and self-harm) are 
the most common causes.  A special interest will be to follow children from pre-puberty until they 
reach 25 years of age to evaluate genetic and environmental predictors for peak bone mass. Detailed 
questionnaire information on causes (event-based) and consequences of the injuries, along with 
genetic and lifestyle characterisation of individuals at high risk of severe or repeated injuries will be 
enabled with detailed prospective characterisation of participants at an especially high risk for the 
development of these diseases.  
Neuro-psychiatric disorders and hearing 
The etiology of most neuro-psychiatric disorders remains cryptic although extant data suggest that 
most have roots in childhood. The national health registers capture inpatient admissions relatively 
well although these constitute a small fraction of population burden. Patient charts from general 
medical settings seldom include psychiatric diagnoses. In the LifeGene neuro-psychiatric working 
group, initial focus was thus on which neuro-psychiatric disorders to consider and, second, which 
might be reasonable to assess with a web-based instrument. Using Swedish data on disability-
adjusted life year estimates obtained from the World Health Organisation (WHO) Global Burden of 
Disease (15) as a guide, the working group defined a list of disorders that were both important and 
practical to assess, along with details about the age ranges of assessment and assessment method. 
Focus was mainly on lifetime prevalence (not current or interval), and need to capture age of onset, 
age of offset, and number of episodes. A set of impulse control disorders of clear public health 
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relevance are also assessed (e.g., pathological gambling). Important disorders such as schizophrenia, 
bipolar disorder, and autism are poorly assessed by the web-based format around which LifeGene 
will be based, so these will be captured via national registers (i.e., the National Patient Register and 
the Prescribed Drug Register). 
The most common cause of hearing loss is genetic (50-70 %). Studies have shown that carriers of 
gene deficits also influence the sensitivity to other risk factors, such as occupational exposures. 
Hearing loss, and its progression, can be caused and/or modified by many different external (e.g. 
exposure at work, day care centres and free time) as well as internal risk factors like genetic and life 
style factors. The prevalence of hearing loss has not been investigated, using audiometric 
measurements, in a large sample of the general population. Hearing tests in LifeGene would provide 
robust knowledge whether the increasing prevalence of hearing loss is true and also validate the self-
estimated hearing. Inclusion of children and young people in LifeGene would also help answering the 
question whether hearing loss in the “MP3/I-pod” generation is increasing and, if so, how this is 
influenced by age and other factors. A prospective study design would also give knowledge of the 
progression of hearing loss over time, both in the population and in individuals (16). 
Physical Activity, Nutrition and Dietary Assessment  
The broad objectives of the Physical Activity, Nutrition and Dietary Assessment (PANDA) working 
group were to investigate the feasibility, validity and reliability of a range of methods for the 
assessment of diet and physical activity suitable for LifeGene. The results from new (LifeGene 
sponsored) and existing studies were summarised, and recommendations on how the measurement 
instruments might be applied in LifeGene were provided. More detail is provided in the pre-pilot 
section, page 22.  
E-epidemiology 
E-epidemiology is the science underlying the acquisition, maintenance and application of 
epidemiological knowledge and information using digital media such as the Internet, mobile phones, 
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digital paper, and digital TV. E-epidemiology also refers to the large-scale science that will 
increasingly be conducted through distributed global collaborations enabled by the Internet (17). A 
critical condition in introducing the Internet and other communication technologies in population-
based studies is the degree of access to the techniques among the population. In 2008, up to 84% of 
the Swedish population used the Internet regularly according to Statistics Sweden. For all age groups, 
using these tools is more common among men than women, but these differences are decreasing 
year to year.  A web-based application for collection of data is easy and inexpensive to construct and 
maintain (18-20). Web technologies also bring possibilities for enhanced data collection not possible 
through the traditional approaches, including real-time data collection, interactivity, tailored and 
personalised questionnaires and repeated measures. Hence, a key feature of LifeGene will be 
exploitation of modern digital tools. 
Sample design and participants 
Baseline study  
Based on the working groups’ recommendations, suggested sample design and recruitment of 
participants was set up. In the sample design finally selected, index persons (aged 18-45 years) will 
be randomly sampled from the general population, with oversampling of twins from the Swedish 
twin registry who have recently been screened with an instrument similar to the LifeGene 
questionnaire. Participants will be invited to include their household members (partner and any 
children). By collecting information on households, shared environmental risks and exposures can be 
quantified. Recruiting children living in the shared household introduces information on persons who 
share environment plus varying degrees of relatedness, as well as contribute to the life course 
information 0-45 years. There will also be provision for spontaneous sign-up, to improve power and 
include participants in a cost-efficient way.  
The planned cohort size of 500,000 participants is the same as recommended by an expert panel 
assembled by the US National Human Genome Research Institute in 2004 (21). For a moderately rare 
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disease (yearly incidence of 50-100 cases per 100,000) and a follow-up of five years, this is expected 
to generate a sufficient number of cases to detect a gene-environment interaction with an odds-ratio 
of 2.5-3 with 80% probability at a conservative significance level of =0.0001 (to protect against false 
positives). This holds under fairly conventional assumptions about allele frequencies, mode of 
inheritance and prevalence of environmental exposures (22).  
Annual follow-ups 
The study participations will be prompted annually to respond to a short, web-based questionnaire 
for updates on changes in household composition, changes in symptoms, injuries and pregnancy.  
Event-based sampling  
The LifeGene study design allows event-based sampling of specific populations. In the early phases of 
LifeGene, three types of event-based sampling will be included.  
1) The LifeGene-Influensa Like Illness (ILI) study addressing influenza in event-based sampling from 
volunteer participants was launched during the LifeGene pilot in September 2009. The LifeGene 
infrastructure and possibilities to sample in response to events was planned before the H1N1 viral 
epidemic emerged. Event-based reports in the LifeGene-ILI allowed sampling prior to disease onset 
(and vaccination), a household sampling triggered by a positive H1N1 or Corona virus diagnosis 
confirmed by PCR and followed by a post-seasonal sampling. DNA, serum and viable peripheral 
mononuclear cells were stored for further analysis. Other tests gauge the immune response directed 
against the current H1N1 strains as well as previous influenza pathogens.  
2) “Born into Cohort”: The LifeGene study design includes recruitment of individuals who may 
become pregnant during the first 6 years of baseline data collection. Thus, LifeGene plans to contact 
pregnant women (and their partners) with additional web-based questionnaire and biosamples 
during pregnancy and delivery. With a target of 500,000 individuals in the cohort, a simulation 
indicates that approximately 21,000 children will be born into the cohort and followed prospectively.  
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3) Injuries: During the annual follow-ups of LifeGene, participants will be asked about injuries during 
the past year. Positive response to these items will generate a more in-depth assessment of causes 
and consequences of these injuries. 
Measures and study procedures  
Based on the recommendations of the working groups, LifeGene was designed to include collection 
of data through web-based questionnaires and in person testing to collect biosamples and a range of 
physical tests, Figure 1. In preparation for the LifeGene pilot, a protocol for web-based 
questionnaires and in-person testing (biosamples and physical examinations) was developed. Names 
and addresses of potential index participants will be randomly sampled from the general population, 
and an invitation letter with personal log-in information sent out. After agreement and consent on 
the LifeGene webpage, they will be able to respond to the LifeGene survey, book an appointment at 
the test centre for in-person testing and invite household members to participate. After the first 
invitation letter, up to three reminders will be sent out. Questions that potential participants may 
have can be directed to the toll-free number of the LifeGene Support Centre, or via the internet. 
Questionnaires  
The LifeGene core survey is designed to collect information about the physical, mental and social 
well-being in the Swedish population, and LifeGene therefore collects data on the diseases and 
disorders most common in Sweden. Extensive sections of the survey are devoted to assessment of 
exposures that may be relevant for these outcomes. All survey data are collected through a web 
portal. 
The LifeGene survey is based on a library that distributes relevant questions to the LifeGene 
participants through a web portal. There are three main categories of study participants entering the 
web portal: adults aged 18 to 45 years (index persons) or older, children invited by index persons and 
the parents to these children. The adult library holds approximately 1,350 questions and the child / 
parent library approximately 1,150 questions.  
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The questions are available to the study participants through a web portal, showing a circular clock-
like menu with questionnaire themes on the dial. Nine themes are shown to adults: Lifestyle, Self-
care, Woman's health, Living habits, Health history, Asthma and allergy, Injuries, Mental health and 
Sociodemography, and between four to nine themes to the partners and children (Figure 2). Parents 
answer for their children aged 0 to 14 and children answer for themselves from 11 and up, which 
means that there are parallel questions to children and parents between the ages of 11 and 14.  
In-person testing  
At the test centres, the study participants are examined for weight, height, waist, hip and chest 
circumference, bioimpedance, heart rate and blood pressure, along with audiometry and spirometry, 
with adaptations in individuals above or below 7 years of age. Blood and urine samples are also taken 
at the test centre for analysis and bio-banking. Table 1 gives details on in-person testing in the 
LifeGene pilot. In adults, EDTA whole blood for DNA and front-end chemistry will be obtained, along 
with tubes of EDTA with gel, citrate, lithium heparin and trace metals. In individuals 7 -18 years old, 
only tubes with EDTA for DNA, EDTA with gel, lithium heparin, trace metals and urinary samples will 
be collected, and for those under 7 years only EDTA whole blood for DNA and a urinary sample.  All 
samples will be aliquoted for subsequent processing and storage. DNA will be extracted concurrent 
with other sample processing initially, to be available for subsequent genotyping. The extent of 
genotyping and choice of platform will be dictated by researcher interest and methodological 
developments.  
Infrastructure 
Biobanking  
The biological samples collected during in-person testing will be transported in a refrigerated chain 
with temperature monitors to a biobank facility where primary sample tubes will be processed and 
stored. The ISO accredited Biobank at Karolinska Institutet is currently establishing new and cost-
effective automated processes to allow for novel high throughput techniques. The input processes 
include registration, volume measurement, sorting with respect to sample type, centrifugation, de-
Formatted: English (U.S.)
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capping and aliquoting of multiple 225 µl plasma and urine fractions into 2D bar-coded tubes and 
DNA extraction from 400 l EDTA blood. Planned processes also include RNA extraction, cell 
isolation, and front-end chemistry based on blood and urine. The storage solution consist of three 
elements: (1) a farm of liquid nitrogen tanks housing tens of millions of samples (2) one or several 
robotic re-picking stations to retrieve desired samples and (3) in the future a large-scale automatic 
freezer.  
The analysis of samples for research takes place after retrieval from storage. Through stringently 
standardized sampling protocols and modern biobanking, LifeGene will provide an opportunity to 
evaluate the full ´omics´ – set including proteomics, metabolomics, genomics and epigenomics. 
Researchers interested in the LifeGene materials will be offered to use external quality-approved 
analytical centres. Some analysis platforms in high demand will be set up in-house. 
IT structure  
For LifeGene IT structure, it will be important to provide a long term platform for data collection and 
withdrawal. We have developed an IT infrastructure and functionality based on process analysis 
applying modular, rather than single, integration solution approach, built on proven industrial 
solutions. Integration has been done using web services based on Microsoft.Net and all research data 
for collection are stored in a central repository with no sensitive data stored at LifeGene test centres.  
Biostatistics 
The household based longitudinal design of LifeGene allows great flexibility in the type of research 
questions that can be addressed. It was emphasised that classical concerns of observational 
epidemiology, such as bias due to selection, confounding and reverse causation are a reality, as well 
as issues of incomplete data due to non-compliance, drop-out and measurement errors.  
For many studies based on LifeGene it may prove useful also to draw on modern statistical methods 
for observational data, as discussed by Hernán and Robins (23). They set up a framework for causal 
modelling, which mimics the rationale for controlled randomised trials, and which can disentangle 
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complex dependencies between time varying exposures and confounders. Referring to the rationale 
in Prentice et al (24) for the Women’s Health Initiative, it is also worth paying attention to the 
systematic and random errors in the assessment of exposures, in particular assessment of dietary 
intake and physical activity, and the implications that these measurement errors may have on the 
estimates of associations between exposure and outcome.  
Special design, quality control and analysis issues arise when dealing with high dimensional multi-
omics data. These may provide biomarker profiles for early detection or a basis for disease 
classification, prognosis and treatment prediction. In particular, metabolomics could meet nutritional 
epidemiology in the search for novel exposure biomarkers that could calibrate traditional measure-
ments for diet and physical activity. Mendelian randomisation could be a useful tool to infer causal 
relationship between a modifiable exposure and disease (25). 
In large randomised controlled trials, it is common practice to augment the original study design with 
observational components. Conversely, randomised components of lifestyle interventions could be 
superimposed on the LifeGene observational cohort (26). This would provide analytic advantages for 
the study of gene-lifestyle interactions, and such “multi-life” interventions would allow volunteer 
participants to take more active part in the LifeGene assembly of data. 
Ethics synopsis  
A document on LifeGene ethics policy including details on recruitment, consent, data and sample 
access and governance has been developed. Further details on the ethics document can be found at 
www.lifegene.se/For-Scientists1/Ethics/ . Permission for the pilot study was obtained from the 
Regional Ethical Review Board of Stockholm, Sweden. Researchers requesting to use the data and/or 
samples will be required to apply for Ethics approval. An impartial data access committee will vet 
requests for access to de-identified data and samples. 
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Results  
In preparation for the pilot, a number of pre-pilots were performed.   
Pre-pilots  
1) Physical activity and dietary assessment methods were validated in pregnant and non-pregnant 
women (aged 20-35 yrs). A physical activity assessment feasibility study was also conducted in young 
mothers and their four month old babies. The studies compared estimates of physical activity energy 
expenditure derived from three activity monitors with validation obtained from the standard 
criterion method of doubly labelled water (DLW).  
2) A meal-based food frequency questionnaire (Meal-Q) was developed for the web-based 
questionnaire and validated against DLW, nutrient-related biomarkers and/or seven days of food 
records in different age groups. Due to limitations on numbers of food items that can be assessed in 
a short time, it is important to adapt the method to diets currently consumed by adults, teens, 
adolescents, children and infants. The selection of food items to be included in Meal-Q was therefore 
based on age-specific studies using 24 hour recall or food records. Physical activity questionnaires 
(Active-Q) were developed that were similarly adapted to the usual domains of leisure and 
occupational activity as well as regular transportations in the various age groups, and  validated using 
DLW, accelerometers and/or seven days records of activities in different age groups.  
3) In another LifeGene pre-pilot, dust samples were collected to assess the stability of allergens and 
endotoxins over time and the variability in allergen content related to fresh, frozen and thawed 
extracts.  
LifeGene Pilot  
Based on the recommendations of the working groups, we performed a full “dress-rehearsal” pilot of 
1% of the target population, i.e. 5,000 tested individuals. Based on the Swedish population, the 
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proposed pilot size allows us to estimate the response rate in each age and sex stratum within 5% 
with 95% probability. The testing sites were chosen to reflect various combinations of geographical 
location, population density, and association with a university. Thus, we chose a large city 
(Stockholm, capital of Sweden with almost 2 million inhabitants), a university city (Umeå, in the north 
with 111,000 inhabitants) and a smaller town (Alingsås, in the west with 36,000 inhabitants).  The 
LifeGene pilot study was launched in Stockholm in October, 2009, followed by the Umeå pilot in late 
November 2009 and Alingsås in January 2010, and all testing was stopped on March 31, 2010. The 
testing schedule was designed to generate the number of participants at the proposed testing 
centres that would stretch the limits of the biobanking facility’s ability to process samples within 
specified parameters and fully test logistics regarding chilled transport. Figure 3 shows the expected 
age distribution of participants in the pilot. 
Influenza pilot  
The LifeGene study design allows event-based sampling. An exercise in this context is the LifeGene 
pilot addressing ‘Influenza-like-illnesses’, ILI. This study was planned before the H1N1 viral epidemic 
emerged. The LifeGene-ILI pilot study included sampling of 2,000 adults prior to disease onset (and 
vaccination), mechanisms for reporting influenza-like symptoms and providing nasal swabs for viral 
analysis, household sampling triggered by a positive H1N1 diagnosis confirmed by PCR and followed 
by a post-seasonal sampling. DNA, serum, plasma and viable peripheral mononuclear cells are stored 
for further analysis; other tests gauge the immune response directed against the current H1N1 
strains, as well previous influenza pathogens.  
The pre-pilots were concluded during the spring of 2009, the actual pilot was stopped by design at 
the end of March, 2010 and is currently being evaluated. Recruitment for the main study will start 
November, 2010 with a gradual expansion of testing centres in the remaining four cities with major 
universities followed by selected locations in smaller towns, and is planned to take six years.  
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Discussion  
LifeGene is a prospective cohort study with the aim to combine advances in modern biotechnology 
and information on individuals' health and lifestyle. A comprehensive baseline questionnaire 
designed to accommodate cutting-edge research questions, state of the art biosampling, repeated 
follow-ups including event-based sampling are key features of this ambitious initiative. The wide 
array of high-tech tools encompassed by e-epidemiology will facilitate the longitudinal aspects of the 
study. Recruitment of index people 18-45 years old, who are invited to include their adult household 
members and children, will increase the opportunity to involve young couples prior to and during 
pregnancy, allowing for the first study of children born into a cohort with complete pre- and 
perinatal data from both mother and father. Furthermore, by focusing on index individuals in young 
and mid-adulthood in a household structure, we will be able to assess exposures and disease 
progression for a myriad of disorders that have considerable consequences not only for health care 
demand, but also for future development of chronic diseases.   
Large population-based studies with repeated collection of questionnaire data and sampling over 
time are extremely costly and the funding has to be well invested. Given the numerous targets that 
have already been identified through other studies throughout the world, care has to be taken when 
designing and planning yet another large-scale study. Future studies have to consider carefully 
whether it is most cost-effective to monitor large populations in prospective cohort studies or 
undertake well-designed case-control studies on a particular exposure or disease (21). It has been 
argued that population-based cohorts are necessary to account for methodological challenges such 
as standardisation and generalisation, to allow for new methodologies and to include younger age 
groups (27). Others suggest that initiating new large population-based cohorts are not worth the wait 
and should be replaced by merging ongoing smaller cohort studies (28). In this context, LifeGene has 
been designed to address a wide variety of research questions, including the possibility of detecting 
pre-clinical markers for disease, event-based sampling and a cohort of children born into the study.  
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We would also like to take this opportunity to invite the scientific community to participate in 
LifeGene, by proposing sub-studies and possible add-ons. The LifeGene project is a national 
population-based study of global importance.  
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Tables and Figures  
Figure 1. Flow chart on the structure of the study. Questionnaires (Q), parental questionnaires (pQ) 
and In Person Testing (IPT) in adults, adolescents and children.   
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Figure 2. Questionnaire modules in adults (a) and children (b)  
a)  
 
Copyright by LifeGene 
b)  
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Figure 3. Population distribution of the LifeGene pilot at the end of the recruitment period.  
Red line: median over 100 simulations, dark grey are: 95% for 100 simulations.  
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Table 1. Biosamples and physical measurements collected during the pilot 
Biosamples Purpose Adults 7-18 yrs <7 yrs 
EDTA whole blood DNA x x x 
EDTA whole blood WBC+diff/HbA1c x   
LiHep with gel Frontend chemistry x   
EDTA with gel Aliquots x x  
EDTA with gel Aliquots x   
Citrate 3.8% Aliquots x   
LiHep with gel Aliquots x x  
Trace metal  Aliquots x x x 
Urine  Aliquots x x x 
 
 
Physical measures >7 yrs 6 yrs 5 yrs <5 yrs 
Height  x x x x 
Weight x x x x 
Bioimpedance  x    
Waist circumference  x x x x 
Hip circumference x x x x 
Thorax circumference x x   
Heart rate  x x x  
Blood pressure x x x  
Audiometry  x x   
Spirometry x x   
 
 
 
 
